Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia

This study has been completed.
Sponsor:
Collaborator:
Novartis
Information provided by:
University of Bologna
ClinicalTrials.gov Identifier:
NCT00511303
First received: August 2, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given